{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:54:05Z","timestamp":1793656445290,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.07.021","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T01:42:35Z","timestamp":1658799755000},"page":"5356-5365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59\u00a0years in China"],"prefix":"10.1016","volume":"40","author":[{"given":"Wang","family":"Shenyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Xiaoqian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Hangjie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Qianhui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhenzhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chuanfu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lv","family":"Huakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.vaccine.2022.07.021_b0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.07.021_b0010","unstructured":"World Health Organization. Coronavirus diseases (COVID-19) Situation Dashboard. Available at: https:\/\/covid19.who.int\/. Accessed 16 February 2022."},{"issue":"9397","key":"10.1016\/j.vaccine.2022.07.021_b0015","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(03)14854-4","article-title":"Influenza","volume":"362","author":"Nicholson","year":"2003","journal-title":"Influenza. Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.021_b0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamapediatrics.2020.4573","article-title":"Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: A systematic review and meta-analysis","volume":"175","author":"Viner","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2022.07.021_b0025","doi-asserted-by":"crossref","first-page":"104554","DOI":"10.1016\/j.micpath.2020.104554","article-title":"Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection","volume":"152","author":"Khorramdelazad","year":"2021","journal-title":"Microb Pathog."},{"key":"10.1016\/j.vaccine.2022.07.021_b0030","doi-asserted-by":"crossref","unstructured":"Kwon T, Gaudreault NN, Richt JA. Seasonal stability of SARS-CoV-2 in biological fluids. Preprint. bioRxiv. 2021;2021.04.07.438866. Published 2021 Apr 8.","DOI":"10.1101\/2021.04.07.438866"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.021_b0035","doi-asserted-by":"crossref","DOI":"10.1111\/ina.12767","article-title":"Author Correction: Routes of transmission of influenza A H1N1, SARS CoV and norovirus in air cabin: Comparative analyses","volume":"31","author":"Lei","year":"2021","journal-title":"Indoor Air"},{"issue":"10236","key":"10.1016\/j.vaccine.2022.07.021_b0040","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S0140-6736(20)31052-7","article-title":"SARS-CoV-2 and influenza virus co-infection","volume":"395","author":"Cuadrado-Pay\u00e1n","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.021_b0045","doi-asserted-by":"crossref","first-page":"e236812","DOI":"10.1136\/bcr-2020-236812","article-title":"Coinfection with SARS-CoV-2 and influenza A virus","volume":"13","author":"Kondo","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.021_b0050","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3201\/eid2606.200299","article-title":"Coinfection with SARS-CoV-2 and influenza A virus in patient with pneumonia","volume":"26","author":"Wu","year":"2020","journal-title":"China. Emerg Infect Dis"},{"issue":"9186","key":"10.1016\/j.vaccine.2022.07.021_b0055","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(99)01241-6","article-title":"Influenza","volume":"354","author":"Cox","year":"1999","journal-title":"Influenza. Lancet"},{"issue":"51","key":"10.1016\/j.vaccine.2022.07.021_b0060","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1016\/j.vaccine.2017.10.096","article-title":"Influenza vaccination in preventing outbreaks in schools: A long-term ecological overview","volume":"35","author":"Pan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.021_b0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.021_b0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.07.021_b0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.021_b0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/vaccines9050529","article-title":"The Association between Influenza Vaccination and COVID-19 and Its Outcomes: A Systematic Review and Meta-Analysis of Observational Studies","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.07.021_b0085","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/infdis\/jiz129","article-title":"Immunogenicity and safety of an Inactivated Enterovirus 71 Vaccine administered concomitantly with Hepatitis B vaccine and Group A Meningococcal Polysaccharide vaccine: a phase 4, open-Label, single-Center, randomized, noninferiority trial","volume":"220","author":"Zhang","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.07.021_b0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.07.021_b0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.07.021_b0100","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2022.07.021_b0105","unstructured":"China National Medical Products Administration. Guidelines for grading standards of adverse events in clinical trials of preventive vaccines. Available at: https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20191231111901460.html. Accessed 16 February 2022."},{"issue":"12","key":"10.1016\/j.vaccine.2022.07.021_b0110","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3201\/eid2512.190261","article-title":"Avian Influenza A Viruses among Occupationally Exposed Populations, China, 2014\u20132016","volume":"25","author":"Quan","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"10263","key":"10.1016\/j.vaccine.2022.07.021_b0115","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","article-title":"Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination","volume":"396","author":"Anderson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.021_b0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory sub-study of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med."},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.021_b0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med."},{"issue":"10318","key":"10.1016\/j.vaccine.2022.07.021_b0130","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","article-title":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial","volume":"398","author":"Lazarus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.07.021_b0135","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2020.06.071","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged \u22653 years","volume":"38","author":"Chu","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.021_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.021_b0145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","article-title":"Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review","volume":"36","author":"Kaur","year":"2021","journal-title":"Indian J Clin Biochem."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:44Z","timestamp":1759403804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22009082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":29,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22009082"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59\u00a0years in China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}